Research programme: HuMax-TAC antibodies - Genmab

Drug Profile

Research programme: HuMax-TAC antibodies - Genmab

Alternative Names: HuMax-TAC

Latest Information Update: 18 Mar 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ADC Therapeutics; Genmab
  • Developer Genmab
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 2 inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • No development reported Transplant rejection

Most Recent Events

  • 18 Mar 2011 No development reported - Preclinical for Transplant rejection in Denmark (Parenteral)
  • 06 Aug 2007 The HuMax-TAC antibodies are still in preclinical trials for the prevention of organ transplant rejection in Denmark
  • 06 Aug 2007 Merck Serono terminates its worldwide licence for the lead HuMax-TAC antibody candidate
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top